Ascendis Pharma Names Chad Fugere Vice President Of Investor Relations
Congratulations to our client AscendisPharma for appointing ChadFugere as VicePresident, InvestorRelations. AscendisPharma is a global biopharmaceutical company focused on applying their innovative TransCon technology platform to make a meaningful difference for patients. AscendisPharma A/S manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. Good day, and welcome to the Third Quarter 2025 AscendisPharma Earnings Conference Call. I would now like to turn the call over to ChadFugere, VicePresidentofInvestorRelations at AscendisPharma. ChadFugere - AscendisPharma A/S-VicePresidentofInvestorRelations.8,000+ Institutional investors’ 13F holdings. Powerful Excel Add-in and Google sheets Add-on. Thank you for standing by and welcome to AscendisPharma's fourth quarter 2025 earnings conference call. At this time, all participants are in listen-only mode.Now I'd like to introduce your host for today's program, ChadFugere, VicePresident, InvestorRelations. AscendisPharma reported a Q4 EPS of -0.55, significantly missing the forecasted -0.15. The revenue of 240 million euros was slightly below the expected 245.68 million euros, marking a 2.31% shortfall. Ascendis expects total 2025 product revenue of about €683 million and a gross margin of approximately 87%. Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes.
Read also: Dallasnews Obits
